Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT04635683
What this trial is testing

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Follicular Lymphoma+21 more
Yazeed Sawalha
Testing effectiveness (Phase 2)Study completedNCT03155425
What this trial is testing

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma, Adult
Jiangsu HengRui Medicine Co., Ltd. 75
Not applicableStudy completedNCT02486952
What this trial is testing

MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

Who this might be right for
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 154
Early research (Phase 1)Looking for participantsNCT06487624
What this trial is testing

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Who this might be right for
Advanced Solid TumorRefractory Hodgkin Lymphoma
FBD Biologics Limited 50
Early research (Phase 1)Active Not RecruitingNCT03321643
What this trial is testing

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT01471210
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb 124
Testing effectiveness (Phase 2)Looking for participantsNCT06244368
What this trial is testing

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 115
Very early researchUnknownNCT04226989
What this trial is testing

CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma
He Huang 72
Early research (Phase 1)Study completedNCT03003546
What this trial is testing

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic Lymphoma+3 more
Mayo Clinic 9
Early research (Phase 1)Study completedNCT01421173
What this trial is testing

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 78
Testing effectiveness (Phase 2)WithdrawnNCT00005969
What this trial is testing

Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT03009344
What this trial is testing

Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd. 7
Early research (Phase 1)Study completedNCT01129180
What this trial is testing

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+9 more
Pierluigi Porcu 8
Early research (Phase 1)Study completedNCT02543879
What this trial is testing

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplastic Syndrome+1 more
Forma Therapeutics, Inc. 94
Testing effectiveness (Phase 2)Study completedNCT03210662
What this trial is testing

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Aggressive Non-Hodgkin LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma+8 more
M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT00053196
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma+3 more
Alliance for Clinical Trials in Oncology 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT05821088
What this trial is testing

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD
Early research (Phase 1)Study completedNCT01900509
What this trial is testing

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia
St. Jude Children's Research Hospital 16
Early research (Phase 1)UnknownNCT02280993
What this trial is testing

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Who this might be right for
Hodgkin LymphomaRefractoryRelapse
Marjolein Spiering 72
Testing effectiveness (Phase 2)Study completedNCT03213691
What this trial is testing

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+8 more
National Cancer Institute (NCI) 21
Next Page
24
37